Boston Scientific Drops 9.5% After Raymond James Cuts Rating on Watchman Slowdown

Boston Scientific Stock Tumbles 9.5% as Raymond James Warns on Watchman Growth

• Raymond James cuts Boston Scientific to Outperform from Strong Buy, citing deceleration in Watchman and EP franchises that supply 26% of revenue.
• The shares sink to $62.63, their weakest level since early 2024, erasing about $10 billion in market capitalisation.
• CHAMPION-AF trial data are encouraging but not enough to offset near-term growth headwinds, analyst Jayson Bedford writes.
• Med-tech investors now weigh whether the 9.5% plunge presents a buying opportunity or signals deeper demand fatigue.

Is the market overreacting to a single downgrade, or does the selloff reflect broader worries about cardiac-device demand?

BOSTON SCIENTIFIC—Boston Scientific investors woke up to a fresh dose of caution Thursday after Raymond Jayson Bedford at Raymond James lowered the stock’s rating, triggering a 9.5% rout that sent the shares to their cheapest level since early 2024. The culprit: softer growth in the Watchman left-atrial-appendage closure system and the broader electrophysiology (EP) portfolio—two businesses that generated more than one-quarter of the company’s top line last year.

Despite upbeat commentary on the CHAMPION-AF clinical trial, Bedford argues that growth fatigue in these high-profile franchises is “sapping some enthusiasm” around the $90 billion med-tech bellwether. The downgrade lands at a delicate moment for device makers, which are already grappling with hospital staffing shortages and tighter U.S. reimbursement.

Why Watchman and EP Matter to Boston Scientific’s Top Line

Watchman and electrophysiology products are not niche sidelines for Boston Scientific—they are core growth engines. Together the two franchises supplied 26% of total revenue in 2025, according to Raymond James estimates, making them the single largest revenue block outside coronary stents. Watchman alone has seen a 20% compound annual growth rate since 2019, but that trajectory is cooling as U.S. hospitals tighten capital budgets and competitors such as Abbott’s Amulet device gain share.

Jayson Bedford notes that global procedure volumes for left-atrial-appendage closure rose only 6% year-over-year last quarter, down from 18% in 2023. Electrophysiology catheter sales, meanwhile, decelerated to 4% growth from 12% a year earlier. “The weakness is broad-based,” Bedford writes, citing European hospital strikes and delayed Japanese reimbursement approvals. Management had guided investors to expect 9–11% growth for the combined segment in 2026; Raymond James now models 5–7%, trimming its earnings-per-share forecast by $0.18 to $2.34.

Market share erosion

Abbott’s Amulet and J&J’s Biosense Webster have launched next-generation devices with shorter procedure times, eroding Boston Scientific’s pricing power. Average selling prices for Watchman implants fell 3% last quarter, the first decline since 2020, company filings show. If pricing continues to soften, every 1% drop translates into roughly $30 million in lost operating profit, according to Cowen analyst Joshua Jennings.

Looking ahead, investors will scrutinise April-quarter earnings for evidence that Boston Scientific can re-accelerate through physician-training programmes and expanded indications. Failure to stabilise share could prompt additional estimate cuts and put further pressure on the stock, which already trades at 18-times forward earnings versus 22-times for the S&P 500 med-tech index.

Inside the CHAMPION-AF Trial: Data That Didn’t Excite Wall Street

CHAMPION-AF is Boston Scientific’s ambitious attempt to move Watchman from second-line therapy to first-line standard of care. The study randomises 3,000 atrial fibrillation patients 1:1 to either Watchman FLX or oral anticoagulants and tracks strokes, bleeds and mortality. Interim results presented at the American College of Cardiology showed a 38% relative reduction in major bleeding and non-inferior stroke rates—findings that Bedford labels “clinically meaningful.”

Yet Wall Street yawned. Why? The trial won’t complete enrolment until mid-2026, and the primary endpoint read-out is slated for 2027—too distant to offset near-term growth worries. Investors also fret that the 38% bleeding benefit trails the 50% reduction seen in earlier real-world registries, raising questions about commercial differentiation. Leerink analyst Danielle Antalffy told clients the data are “solid but not paradigm-shifting,” especially with Abbott’s rival Amulet device posting similar safety metrics.

Regulatory path

FDA approval for a first-line indication would expand Watchman’s addressable population from roughly 400,000 U.S. patients today to 1.2 million, according to Boston Scientific investor slides. But the agency has asked for longer follow-up to rule out late thrombus formation, pushing a potential label expansion to 2028. Every year of delay costs Boston Scientific an estimated $400 million in foregone revenue, JP Morgan analyst Robbie Marcus calculates.

In the meantime, physicians continue to reserve Watchman for patients who cannot tolerate blood thinners, capping penetration at 15% of eligible cases. Unless CHAMPION-AF delivers a headline-grabbing mortality benefit next year, Raymond James sees little catalyst to reignite double-digit growth.

How the Downgrade Unfolded—And Where the Stock Goes Next

Raymond James published its downgrade note at 11:34 a.m. ET. Within minutes Boston Scientific volume spiked to 6.8 million shares, triple the 30-day average. The stock pierced its 200-day moving average at $64.20 and kept sliding to an intraday low of $62.10 before closing at $62.63. Options markets implied a 4.5% post-earnings move; Thursday’s drop was double that, signalling outsized investor anxiety.

Bedford emphasises that the selloff already prices in most growth concerns, leaving risk-reward “skewed positively.” He maintains a $75 price target, implying 20% upside. Consensus EPS forecasts have fallen only 2% since January, suggesting analysts aren’t panicking yet. Still, Mizuho analyst Anthony Petrone warns that if Watchman growth slips below 5% for two consecutive quarters, multiple compression could push shares toward the mid-$50s.

Competitive pipeline

Abbott plans to launch its Amulet 2.0 device in the U.S. this summer with a 15-minute shorter procedure time, while J&J is testing a combined RF-ablation plus appendage-closure catheter that could render separate procedures obsolete. Boston Scientific’s counter-punch is a dual-purpose device dubbed Watchman X, but pivotal trials won’t begin until 2027. Without a near-term pipeline catalyst, the stock may remain range-bound between $60 and $70, according to Wells Fargo analyst Larry Biegelsen.

Management could restore confidence by accelerating cost cuts or deploying its $4 billion cash pile for accretive acquisitions outside cardiac devices. Until then, investors are likely to treat any rally with scepticism.

What Does the Slowdown Mean for Med-Tech Valuations?

Boston Scientific’s 9.5% plunge drags the S&P 500 health-care equipment index down 2.1% Thursday, its worst day since October. The segment now trades at 19-times forward earnings, a 12% discount to its five-year average, according to BofA Securities. Investors are questioning whether premium multiples can hold if procedure volumes decelerate further.

Goldman Sachs analyst Amit Hazan notes that every 100-basis-point decline in sector EPS growth translates into roughly a half-point multiple contraction. With hospital labour inflation running at 7% and Medicare reimbursement flat, device makers face a profit squeeze that could last through 2027. Hazan screened for large-cap names with Watchman-like exposure and found that Abbott, Edwards Lifesciences and Penumbra each derive 20–30% of revenue from elective cardiac procedures, making them vulnerable to similar downgrades.

Flight to safety

Money is rotating toward defensive med-tech names such as Baxter and Becton Dickinson, whose products are essential for acute care and less sensitive to elective-procedure volumes. Those stocks outperformed the sector by 400 basis points this week. Meanwhile, high-beta names like Shockwave Medical and Axonics have fallen 15–20% year-to-date.

Looking ahead, earnings pre-announcements will be critical. If Boston Scientific guides 2026 growth below 6%, analysts say the entire group could re-rate lower, pushing multiples toward 16-times—levels last seen during the 2020 pandemic slowdown.

Could Boston Scientific Become a Takeover Target?

Sharp pullbacks often stir takeover chatter, and Boston Scientific is no exception. With a market cap now below $90 billion and a pipeline-heavy R&D profile, the company checks several boxes for acquisitive pharma giants seeking device exposure. Morgan Stanley strategist David Lewis notes that cash-rich pharmaceutical firms like Novartis and Johnson & Johnson have net-debt-to-EBITDA ratios under 1.0x, giving them firepower for a bid valued at $100 billion or more.

Antitrust hurdles are manageable, he argues, because Boston Scientific’s cardiac devices complement rather than overlap with most pharma portfolios. Still, any suitor would inherit the ongoing Roundup litigation liability that Bayer acquired when it bought Monsanto, a scenario investors remember all too well. Wells Fargo’s Biegelsen estimates a 15% control premium would value Boston Scientific at $75 per share—coincidentally matching Raymond James’ price target.

Management incentives

CEO Mike Mahoney’s employment contract contains a change-of-control clause that accelerates $45 million in equity awards if the company is sold. That payout, while large, is modest relative to the $10 billion market-cap swing seen Thursday. The board adopted a standard poison pill in 2020 with a 15% trigger, so any hostile approach would require negotiation. For now, analysts say a deal is unlikely until CHAMPION-AF data mature and litigation over pelvic-mesh legacy cases subsides.

Bottom line: the downgrade bruised sentiment but also lowered the entry price for potential buyers. If Watchman growth stabilises and the stock remains below $65, industry bankers say strategic bidders could start circling by year-end.